Benzinga··Vandana SinghAngelini Pharma Acquires Catalyst Pharmaceuticals for $4.1B in Rare Disease Push
Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion at $31.50 per share, with concurrent patent litigation resolution for rare disease drug Firdapse.
CPRXacquisitionM&A